logo Hematology/Oncology Research Studies: Open for Enrollment Date: 10/22/18

Category: ONCOLOGY: EARLY PHASE

Two-Part Study of TB-403 in Pediatric Subjects with Relapsed or Refractory Medulloblastoma, Neuroblastoma, Ewing Sarcoma or Alveolar Rhabdomyosarcoma

NCT#/Phase: NCT02748135
Phase 1/2a
IRB#: 2017-038
Description: This study will evaluate the safety and efficacy of a monoclonal antibody directed against placental growth factor (PlGF) for patients with relapsed or refractory medulloblastoma (MB), neuroblastoma (NB), alveolar rhabdomyosarcoma (ARMS) or Ewing Sarcoma (ES).
Inclusion: Individuals who are between 6 months and 18 years of age with MB, NB, ES or ARMS who have documented relapse or refractoriness after at least 1 line (MB and ARMS subjects) or 2 lines (NB and ES subjects) of standard-of-care therapy.
Enrollment Status: Open for enrollment
Sponsor: Beat Childhood Cancer (BCC) and Oncurious NV
Principal Investigator(s): Jennifer Michlitsch, MD
Contact(s): Jennifer Michlitsch, MD (510-428-3885 x3264)
Anu Agrawal, MD
Study Link: https://clinicaltrials.gov/ct2/show/NCT02748135

UCSF Benioff Children's Hospital Oakland • 747 52nd Street, Oakland, California 94609 &bull Phone: (510) 428-3000